United States: Ready To Release A New Pharmaceutical? What To Think About When Selecting Your Drug Name

Pharmaceutical name clearance in the United States can be complicated. This post aims to provide insight into the regulatory safety review process and the trademark registration process for candidate drug names. This information will allow drug manufacturers to make more informed decisions during the pharmaceutical name selection process so that they can arrive at a viable name, and get to market, more quickly.

Dual Tracks: FDA and PTO

A pharmaceutical manufacturer that seeks to use and register a new drug name in the United States must submit the candidate name to not one, but two, federal agencies: the U.S. Food and Drug Administration (FDA) and the U.S. Patent and Trademark Office (PTO). While both federal agencies aim to improve consumer safety by reducing the risk of consumer confusion between conflicting drug names, each agency looks at a different set of data to make its determination. The approval of a drug name by one agency has no bearing on the evaluation or approval of that name by the other agency. In addition, while PTO approval of a drug name is important, FDA approval is essential – without it, the product simply cannot be marketed in the U.S. under that name.

FDA Review

As part of the FDA's overall evaluation of a new drug, the agency assesses the manufacturer's proposed "proprietary name," or trademark, for safety risks. The primary safety risk associated with a drug name is the risk of medication error.

A medication error can occur at any point along the distribution chain – by doctors writing the prescription, pharmacists filling the prescription, or patients or health care providers administering the drug. A medication error can also occur for a variety of reasons. Perhaps the drug name suggests the frequency of administration which could conflict with a doctor's instructions. Consider a doctor that prescribes a hypothetical drug called XyzOnce for use twice a day. Will some patients be confused about how often to take the drug? Or perhaps the new drug name suggests the route of administration. If a patient receives a medication in liquid form called XyzOra, will the patient automatically assume that it is intended for oral ingestion? This could cause serious adverse consequences if the drug is, in fact, designed for topical administration. One important way the FDA seeks to reduce medication errors is to evaluate a new drug name to determine whether it looks or sounds too much like an existing drug name and whether that similarity – combined with similarities in the product characteristics – creates an undue safety risk that requires rejection of the candidate drug name.

"Look Alike" Concerns

The driving question for the "look alike" evaluation is whether two names will look similar when handwritten or entered electronically into a prescription.

The FDA considers spelling similarities such as whether two names share identical prefixes, suffixes, or infixes, and whether the names are a similar length. The FDA also considers the overall "shape" of the words. Do both names have similar looking letters in similar positions in the names – including "tall" letters ("l" "t" "f"), "round" letters ("o" "a" "c" "e" "u"), cross-stroke letters ("T" "Z" "F" "J" "I"), or down-stroke letters ("v" "r" "n" "u")? The FDA will balance these factors, along with an analysis of the phonetic similarities, to determine the overall similarity between two drug names.

"Sound Alike" Concerns

The driving question for the "sound alike" evaluation is whether two names will sound similar when spoken. What does the patient hear when the doctor tells him what medicine he has to take – and what does he repeat to the pharmacist? What does the pharmacist hear on a recorded voicemail or over a poor telephone connection? The FDA considers, among other factors, the number of syllables in the names, the placement of vowel sounds, consonant sounds, and stresses, and the placement of common sound alike letters. For example, the sound produced by "t" may be similar to the sound produced by "d" or "k". The sound produced by "b" may be similar to the sound produced by "p" "v" or "d."

Evaluation Process

To evaluate each new drug name, the FDA convenes an expert panel that reviews both objective and subjective criteria. To obtain an objective assessment of the similarity of two drug names, the FDA runs the new drug name through its Phonetic and Orthographic Computer Analysis ("POCA") database. The POCA database evaluates the candidate name against all active drug names in the U.S. market. The database assigns a percentage evaluation, ranking the new drug name on phonetic similarity, orthographic similarity, and an average of the two. Any ranking of 70% or higher will invite additional scrutiny by the agency. The FDA also conducts prescription simulation studies in which it asks volunteers to write out prescriptions, read handwritten prescriptions, and listen to voicemail recordings for the new drug name. The agency then analyzes the results to see what types of mistakes were made and how often. Safety evaluators assemble all the available data on whether the candidate name is likely to be confused with existing names, compares the product characteristics of the drugs to determine whether they have similar indications, dosages, administration methods, or storage requirements, which would increase the risk of medication errors, and make overall determinations as to whether the candidate name is likely to pose safety risks due to possible confusion with existing names.

PTO Review

When the PTO receives a new trademark application for a pharmaceutical product, a PTO attorney will evaluate the application to determine whether the new trademark is inherently registrable, whether the new trademark conflicts with a prior trademark application or registration, and whether the trademark application complies with the PTO's rules.

Inherent Registrability

For a mark to be "inherently registrable" it must be distinctive enough that consumers will perceive it as a brand name instead of a description of the underlying product. For example, consumers would be likely to perceive the hypothetical name "Cancer Drug" as merely describing what the product is (a drug to treat cancer) rather than as a brand name that identifies the manufacturer. The PTO would likely refuse this type of name on the basis that it is "merely descriptive."

The PTO also prohibits registration of names that are "deceptively misdescriptive." For example, consumers would be likely to perceive a drug called "Anti-Cancer" as being indicated for use as a treatment for cancer. That name would be "deceptively misdescriptive" if the drug were actually indicated for use as an insomnia treatment, not a cancer treatment. The PTO would thus bar registration of this name for insomnia treatments.

Conflict with Prior Marks

The PTO also evaluates new trademark applications to determine whether the trademark is likely to cause confusion with a mark in a prior registration or pending application. Due to the risk of consumer harm arising out of confusion between drug names, the PTO rules impose a stricter standard on trademark applications covering pharmaceuticals than on applications covering other types of goods, and less proof is required for the PTO to refuse a pharmaceutical application based on likelihood of confusion.

Unlike the FDA which looks at potential confusion between the candidate name and all approved brand names and generic drugs in the U.S. market, the PTO looks only at potential confusion with trademarks that are covered by an active U.S. application or registration. The PTO analyzes the risk of confusion based on a number of non-exclusive factors including, among others: (i) the similarities of the trademarks in terms of appearance, sound, meaning, and overall commercial impression, (ii) the relatedness of the goods, (iii) the similarities in the target consumers, (iv) the similarities in the trade channels, (v) whether purchases are made on impulse or after careful consideration, and (vi) the number and nature of similar marks used on similar goods.

The first two factors are typically the most important and they operate on a sliding scale: the more similar the marks are, the less similar the goods must be for the PTO to find a "likelihood of confusion." The PTO considers the overall visual, phonetic, and conceptual impression created by two trademarks; it does not do a letter-by-letter analysis like the FDA. Similarly, in evaluating the similarity of the goods, the PTO is bound by the description of goods identified in the respective trademark filings. Unless the description of goods in a trademark filing specifies a mode of administration (i.e., "by injection") or a specific trade channel (i.e., "administered by health care professionals in a clinical setting"), the PTO will not consider such distinctions in evaluating the relatedness of the goods.

Compliance with PTO Rules

To proceed to registration, a trademark application must also comply with a number of technical rules at the PTO. Two rules that can trip up pharmaceutical trademark applicants are the rules to identify the goods with "particularity" and the rules to show use of the mark in commerce.

The PTO requires that trademark applicants specify the nature and purpose of the drug. In other jurisdictions, the description "pharmaceutical preparations" may be acceptable, but the PTO requires more specificity, such as "pharmaceutical preparations, namely, anti-depressants." It is possible to register similar marks for pharmaceuticals covering unrelated indications.

The PTO is relatively unique in that it requires proof that a trademark has been "used in commerce" prior to issuance of a registration. In the pharmaceutical context, shipments of branded drugs to clinical investigators during the regulatory approval process is considered "use in commerce." Trademark applicants that file a U.S. application through the Madrid Protocol or based on a registration in the applicant's home country are not required to submit evidence of use prior to issuance of a registration.

Practical Tips

To streamline the process to regulatory approval and trademark registration for a candidate drug name, pharmaceutical manufacturers may consider adopting the following practices:

  • Start the name clearance process as early as possible to leave sufficient time to conduct preliminary trademark clearance searches, full trademark clearance searches, and to file trademark applications prior to submitting the name for regulatory approval.
  • Have many backup names comprised of a variety of prefixes, suffixes, and infixes, to reduce the risk that a particular prior mark would block multiple candidate names. It is not uncommon for pharmaceutical manufacturers to start with a list of more than 20 candidate names.
  • Consider repurposing a name that was cleared for a prior drug, but not utilized.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.